Efficacy and Safety of Prophylactic Antibiotics in Preventing Ventilator-associated Pneumonia: A Randomized, Double Blind, Placebo-controlled Trial

Esraa Salah Mohamed Abdallah Eladl

Status: Invitation-only

Conditions: Ventilator-Associated Pneumonia (VAP)

Treatments: Drug: Beta Lactam Antibiotics; Drug: Salin

Study type: Interventional

Funder types: Other

Identifiers

NCT07203638

MD 1-11-2024

Details and patient eligibility

About

Evaluate efficacy and safety of prophylactic antibiotics in preventing early ventilator-associated pneumonia

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age > 18 years or older

  • Both sexes will be included.
  • Invasive mechanical ventilation

Exclusion criteria

• ongoing pneumonia or gross aspiration confirmed by the presence of lung infiltrates on chest radiographs at admission before invasive ventilation

  • previous lung disease precluding accurate interpretation of chest radiographs
  • ongoing antibiotic therapy or during the week before admission
  • known chronic colonization with multidrug-resistant bacteria
  • known allergy to beta-lactam antibiotics
  • Pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

100 participants in 2 patient groups, including a placebo group

B.lactam

Active Comparator group

Description:

Patient recieved beta lactam iv 1gm each 12h for 2 days

Treatment:

Drug: Beta Lactam Antibiotics

Control group

Placebo Comparator group

Description:

patients in the control group will receive saline iv each 12h for 2 days

Treatment:

Drug: Salin